Schizophrenia

Machine learning models trained on electronic health record data were able to successfully predict diagnostic progression to schizophrenia and bipolar disorder among patients with other mental illnesses, according to study results.

The incidence of cannabis use disorder associated with schizophrenia almost tripled among Canadian teenagers and adults after cannabis legalization, according to a study published in JAMA Network Open.

Genetic predisposition for schizophrenia and frequent use of cannabis both independently corresponded with an increased likelihood of developing psychosis, results of a case-control study showed.

Genetically predicted major depression may present in women, but not men, with increased risk for arrhythmia disorders, coronary artery disease and heart failure, and risk may vary based on menopausal status, researchers reported.

Individuals who visited the ED for hallucinogen use had a greater risk for developing a schizophrenia spectrum disorder compared with the general population and ED visits for other substances, researchers found.

SAN ANTONIO —An intestinal microsomal triglyceride transfer protein inhibitor reduced postprandial triglycerides and halted weight gain in patients treated with the antipsychotic olanzapine, according to results of a pilot study.

According to published results, severe mental illnesses, such as schizophrenia and bipolar disorder, may be risk factors for decreased bone mineral density, fragility fractures and undiagnosed osteoporosis.

Adults with a schizophrenia spectrum disorder had increased risk for severe infection outcomes while exposed to antipsychotics compared with nonexposure periods, according to a study published in The Lancet Psychiatry.

Obscured by the celebratory congratulations and profuse praise of the scientific advance marked by the FDA’s approval of KarXT, now branded Cobenfy, is the revealing and instructive story of how this novel therapeutic agent came to fruition.